Research
Hormonal
Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.
Healthcare providers should consider these challenges when prescribing GLP-1 therapies.
StrongSupportsmedium confidence
These treatments present several clinical challenges, including high costs, the need for peptide injections, and requirements for repeated administration.
Why this rating
The claim is based on a comprehensive overview of current therapies.
Source
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Yining Xu et al. · Endocrine Reviews · 2025
DOI 10.1210/endrev/bnaf027
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →